Pharmacological approaches to tinnitus have remained peripheral within research, despite persistent patient demand and advances in auditory neuroscience. There is increasing consideration of whether these developments now justify renewed focus on pharmacological research in tinnitus and hyperacusis....
No approved pharmacological treatments for tinnitus or hyperacusis emerged from this review; clinicians should not change prescribing practice based on this conference summary alone.
Mapping the mechanistic and biomarker landscape for tinnitus and hyperacusis is a prerequisite for designing effective drug trials, making this a foundational contribution to the field.
- 01Covers pharmacological mechanisms relevant to tinnitus and hyperacusis treatment.
- 02Highlights the importance of biomarkers for patient stratification in future trials.
- 03Clinical heterogeneity among tinnitus/hyperacusis patients is identified as a key barrier to drug development.
- 04Insights drawn from an international scientific meeting, not a clinical trial.
- 05No specific drug or treatment is currently endorsed by the evidence reviewed.
Biomarkers could enable better patient stratification for tinnitus and hyperacusis pharmacological trials.
opinionpartially supportedClinical heterogeneity is a major obstacle to developing effective pharmacological treatments for tinnitus and hyperacusis.
opinionsupported- PMID
- 42192763
- DOI
- 10.3390/brainsci16050450.
- Journal
- Brain Sciences
- Publication type
- review
- Evidence level
- 5
- Population
- Not applicable — conference proceedings summary
- Intervention
- Pharmacological approaches to tinnitus and hyperacusis
Primary outcomes
Mechanistic understanding of tinnitus and hyperacusis; Identification of relevant biomarkers; Characterisation of clinical heterogeneity